Skip to main content
SpringerLink
Log in

Potentiation of the efficacy of murine L1210 leukemia vaccine by a novel immunostimulator 7-thia-8-oxoguanosine: Increased survival after immunization with vaccine plus 7-thia-8-oxoguanosine

  • Original articles
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Summary

We have investigated the ability of a novel immunopotentiator, 7-thia-8-oxoguanosine (7T8OG) to increase the efficacy of a weakly immunogenic murine L1210 leukemia vaccine. The vaccine was prepared by irradiating L1210 leukemia cells in a cesium source with a total of 6000-R dose. DBA/2 mice were treated with 150 mg/kg 7T8OG and/or with vaccine consisting of 107 irradiated cells. In combination therapy, mice first received the vaccine and then were injected with 75 mg/kg 7T8OG 2 h and 4 h after vaccination. One week after the last treatment all mice were inoculated with 104 live leukemia cells intraperitoneally. Control, untreated mice (n = 66) injected with 104 live leukemia cells had a mean survival time ± standard error of 10.5±0.2 days. Treating mice (n = 66) with one, two or three doses of 7T8OG administered i.p. 1 week apart did not increase survival (mean survival time = 10.7 days). Mice immunized with one, two or three doses of vaccine had 14.5±1.1, 45.4±6.2 and 68.3±10.6 days mean survival, respectively. 7T8OG-stimulated vaccination increased the survival dramatically. The best survival was noted when the mice were treated with 2× (vaccine + 7T8OG). Immunization of mice (n = 30) with this treatment regimen increased the mean survival to 156±10.0 days. Over 90% of mice that were treated this way had a cumulative survival time greater than 160 days. In contrast, only 12% of the mice immunized twice with the leukemia vaccine alone survived over 160 days. These results suggest a rationale for the use of this immuno-potentiator with various vaccines for a more effective immunization.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Arlinhaus RB (1989) Vaccines against tumor antigens. Adv Vet Sci Comp Med 288: 309

    Google Scholar 

  2. Berzofsky JA (1988) Immunodominance in T lymphocyte recognition. Immunol Lett 18: 83

    Google Scholar 

  3. Bystryin JC, Jacobsen S, Harris M, Roses D, Sprayer J, Levin M (1986) Preparation and characterization of a polyvalent human melanoma antigen vaccine. J Biol Response Mod 5: 211

    Google Scholar 

  4. Cantrell JL, Finn DJ (1987) Role of novel adjuvants in specific active immunotherapy. In: Mitchell MS (ed) Progress in clinical and biological research; immunity to cancer: II. Liss, New York, p 297

    Google Scholar 

  5. Cox DR, Oakes D (1984) Analysis of survival data. Chapman and Hill, London, p 1

    Google Scholar 

  6. Dixon WJ (1985) BMDP statistical software. University of California Press, Berkley

    Google Scholar 

  7. Djeu JY, Heinbaugh JA, Holden HJ, Herberman RB (1979) Augmentation of mouse natural killer cell activity by interferon and interferon inducers. J Immunol 122: 175

    Google Scholar 

  8. Earl PL, Moss B, Morrison RP, Wehrly K, Nishio J, Chesebro B (1986) T lymphocyte priming and protection against Friend leukemia by vaccinia-retrovirusenv gene recombinant. Science 234: 728

    Google Scholar 

  9. Gidlund MA, Orn A, Wigzell H, Senik A, Gresser I (1978) Enhanced NK cell activity in mice injected with interferon and interferon inducers. Nature 273: 759

    Google Scholar 

  10. Hanna MG, Peters LC (1978) Immunotherapy of established micrometastases with bacillus Calmette-Guerin tumor cell vaccine. Cancer Res 38: 204

    Google Scholar 

  11. Hoover HC, Surdyka MS, Dangel RB, Peter LC, Hanna MG (1985) Prospectively randomized trial of adjuvant active-specific immunotherapy for human colorectal cancer. Cancer 55: 1236

    Google Scholar 

  12. Kalbfeisch JD, Prentice RL (1980) The statistical analysis of failure time data. Wiley, New York, p 1

    Google Scholar 

  13. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observation. J Am Statist Assoc 58: 457

    Google Scholar 

  14. Lee V, Sharma B, Jolley WB (1989) 7-Thia-oxoguanosine induces de novo expression of surface Ia antigens and Ig. FASEB J 3: 794

    Google Scholar 

  15. Livingston PO (1987) Experimental and clinical studies with active specific immunotherapy. In: Mitchell MS (ed) Progress in clinical and biological research; immunity to cancer: II. Liss, New York, p 309

    Google Scholar 

  16. Mitchell MS (1987) Active specific immunotherapy in the treatment of human cancers. In: Mitchell MS (ed) Progress in clinical and biological research: immunity to cancer: II. Liss, New York, p 323

    Google Scholar 

  17. Nagahara, Anderson J, Kini G, Dalley K, Larson S, Smee D, Sharama B, Jolley WB, Robins RK, Cottam B (1990) Thiazolo [4-5-d]-pyrimidine nucleosides. The synthesis of certain 3-β-d-ribo-furanosylthiazolo [4,5-d] pyrimidines as potential immunotherapeutic agents. Med Chem 33: 407

    Google Scholar 

  18. Neidhart JA, Murphy SC, Hennick LA, Wise HA (1980) Active Specific immunotherapy of stage IV veral carcinoma with aggregated tumor antigen adjuvant. Cancer 46: 1128

    Google Scholar 

  19. Prehn RT (1973) The immune reaction as a stimulator of tumor growth. Science 176: 70

    Google Scholar 

  20. Rosa FM, Cochet MM, Fellus M (1986) Interferon and major histocompatibility complex genes: a model to analyze eucaryotic gene regulation. Interferon 7: 47

    Google Scholar 

  21. Sahasrabudhe DM, Dekernion JB, Pontes JE, McCune CS, Ryan DM, O'Donnel RW (1986) Specific immunotherapy with suppressor functional inhibition for metastatic renal cell carcinoma. J Biol Response Mod 5: 581

    Google Scholar 

  22. Schiel HJ, Kyewski B, Oegen P, Schirrmacher V (1987) CD4+ helper T cells are required for resistance to highly metastatic murine tumor. Eur J Immunol 17: 1863

    Google Scholar 

  23. Sharma B, Odom LF (1979) Generation o killer lymphocytes in vitro against autologous leukemia cells with leukemic blast and BCG extract. Cancer Immunol Immunother 7: 99

    Google Scholar 

  24. Sharma B, Kohaio O, Mickey MR, Terasaki PI (1975) Effect of water soluble adjuvany on in vitro lymphocyte immunization. Cancer Res 35: 666

    Google Scholar 

  25. Sharma B, Jolley WB, Popow J, Robins RK, Cottam H (1988) N10 146, a novel nucleoside induces B cell proliferation, polyclonal antibody synthesis and enhances antigen specific primary antibody response. In: Proc. 3d Annual Conference on Clinical Immunology, San Francisco, p 27

  26. Sharma B, Jin A, Balazs L, Mhaskar S, Jolley WB (1989) Inhibition of metastatic growth of murine melanoma tumor cells in lungs by 7-thia-8-oxoguanosine. FASEB J 3: 831

    Google Scholar 

  27. Smee DF, Alaghamandan HA, Cottam HB, Sharama B, Jolley WB, Robins K (1989) Broad-spectrum in vivo antiviral activity of 7-thia-8-oxoguanosine, a novel immunopotentiating agent. antimicrob Agents Chemother 33: 1487

    Google Scholar 

  28. Smee DF, Alaghamanadan HA, Jin A, Sharma B, Jolley WB (1990) roles of interferon and natural killer cells in the antiviral activity of 7-thia-8-oxoguanosine against Semiliki forest virus in mice. Antiviral Res 13: 91

    Google Scholar 

  29. Vanky F, Stuber G, Willems J, Sjowall K Larsson, Book K, Invert T, Peterffy A, Klein E (1988) Importance of MHC antigen expression on solid tumors in the interaction with autologous blood lymphocytes. Cancer Immunol Immunother 27: 213

    Google Scholar 

  30. Vanky F, Stuber G, Rosteim S, Klein E (1989) Auto tumor recognition following in vitro induction of MHC antigen expression on solid human tumors: stimulation of lymphocytes and generation of cytotoxicity-negative tumor cells. Cancer Immunol Immunother 28: 17

    Google Scholar 

  31. Wu J, Fitzgerald J, Sonis S, Ravikumar T, Wilson R (1987) Increased efficacy of immunotherapy using irradiated tumor cells. Cancer Immunol Immunother 24: 68

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. ICN Nucleic Acid Research Institute, 3300 Hyland Ave, 92 625, Costa Mesa, CA, USA

    Brahma S. Sharma, Louisa Balazs, Ai Jin, James Chyan-Ji Wang, Weldon B. Jolley & Roland K. Robins

Authors
  1. Brahma S. Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Louisa Balazs
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ai Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. James Chyan-Ji Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Weldon B. Jolley
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Roland K. Robins
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sharma, B.S., Balazs, L., Jin, A. et al. Potentiation of the efficacy of murine L1210 leukemia vaccine by a novel immunostimulator 7-thia-8-oxoguanosine: Increased survival after immunization with vaccine plus 7-thia-8-oxoguanosine. Cancer Immunol Immunother 33, 109–114 (1991). https://doi.org/10.1007/BF01742538

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01742538

Key words

Search

Navigation